TrialThe journal of headache and pain2022
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
Roberto De Icco et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this paperpooled ittrialcites it